# MYBL1 Gene: Structure, Function, and Clinical Significance
## Key Takeaways
- MYBL1 encodes a MYB-family transcription factor essential for cell cycle regulation, differentiation, and meiosis, binding to the consensus DNA motif YAAC(G/T)G. Its structure features a conserved N-terminal DNA-binding domain (DBD) with three helix-turn-helix repeats, a transactivation domain (TAD), and a negative regulatory domain (NRD).
- Aberrant MYBL1 activity, often due to truncating rearrangements that remove the NRD, drives oncogenesis in adenoid cystic carcinoma (ACC) via MYBL1-NFIB fusions and in pediatric low-grade gliomas (PLGGs), including isomorphic diffuse gliomas (IDGs).
- MYBL1 plays a critical role in male spermatogenesis, with its disruption leading to meiotic arrest; specific intronic SNPs have been associated with male infertility in certain populations.
- In triple-negative breast cancer (TNBC), MYBL1 overexpression, often linked to copy number gains at 8q13.1, contributes to tumor progression and is associated with dysregulation of genes like VCPIP1.
- MYBL1 is a key component of the BCL6 transcriptional program in germinal center B cells, and its expression level serves as a prognostic biomarker for classifying diffuse large B-cell lymphoma (DLBCL) subtypes.
- Therapeutic strategies targeting MYBL1 are under investigation, including BET inhibitors, CDK2 inhibitors, antisense oligonucleotides (ASOs), and PROTACs designed for targeted protein degradation, often in combination with other MYB family inhibitors.
---
## Executive Summary & Key Metadata
The MYBL1 gene (v-myb avian myeloblastosis viral oncogene homolog-like 1), also known as A-MYB, encodes a member of the MYB family of transcription factors. This family, which includes MYB (c-MYB), MYBL1 (A-MYB), and MYBL2 (B-MYB), is characterized by a highly conserved N-terminal DNA-binding domain (DBD) composed of three tandem repeats (R1, R2, R3), each adopting a helix-turn-helix variant motif. MYBL1 functions as a sequence-specific transcriptional activator that binds to the consensus DNA sequence YAAC(G/T)G, playing critical roles in cell cycle regulation, differentiation, and germ cell development. Clinically, MYBL1 is a recognized oncogenic driver in several malignancies, most notably adenoid cystic carcinoma (ACC), pediatric low-grade gliomas (PLGGs), and triple-negative breast cancer (TNBC). Its involvement in male infertility, immune regulation, and viral pathogenesis has also been documented.
| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | MYBL1 |
| **UniProt Accession** | P10243 |
| **Representative PDB ID** | true (structural models available via homology; see Section 2) |
| **Chromosomal Locus** | 8q13.1 (GRCh38: chr8:67,073,789-67,115,641; minus strand) |
| **Primary Molecular Function** | Sequence-specific DNA-binding transcription factor (activator); regulates cell cycle, differentiation, and meiosis |
| **Disease & Pathology Associations** | Adenoid cystic carcinoma (ACC), pediatric low-grade glioma (PLGG), isomorphic diffuse glioma (IDG), triple-negative breast cancer (TNBC), diffuse large B-cell lymphoma (DLBCL), male infertility, sepsis-induced cardiomyopathy |
---
## 1. Genomic Locus, Chromosomal Organization & Isoforms
### 1.1 Chromosomal Location and Gene Structure
MYBL1 is located on the long arm of chromosome 8 at cytogenetic band 8q13.1. The gene spans approximately 41.9 kilobases (kb) of genomic DNA on the minus (reverse) strand. The precise coordinates in the GRCh38/hg38 assembly are chr8:67,073,789–67,115,641. The gene is oriented in a head-to-head configuration with the neighboring gene *MYBL1-AS1* (antisense RNA), suggesting potential cis-regulatory crosstalk. The 8q13.1 locus is notable for recurrent copy number alterations in multiple cancer types, including amplification in oral squamous cell carcinoma and TNBC [1][2].
The MYBL1 gene comprises 15 exons, with the translation initiation codon located in exon 2 and the stop codon in exon 15. The canonical transcript (NM_001080416.2) is 3,456 nucleotides in length and encodes a protein of 752 amino acids with a predicted molecular mass of approximately 86 kDa [3]. The intron-exon boundaries are conserved across mammals, with the largest intron (intron 2) spanning approximately 8 kb and containing multiple regulatory elements, including a CpG island and binding sites for the insulator protein CTCF [4].
### 1.2 Promoter Architecture and Regulatory Elements
The MYBL1 promoter lacks a canonical TATA box but contains a high-density CpG island (CpG island 113) that extends from the 5' untranslated region into intron 1. This CpG island is subject to dynamic DNA methylation, with hypomethylation observed in germ cells and hypermethylation in somatic tissues, correlating with the tissue-specific expression pattern of MYBL1 [5][6]. The promoter region contains multiple binding sites for transcription factors, including:
- **E2F family members**: E2F1 and E2F4 binding sites are located within 500 bp upstream of the transcription start site (TSS). These sites mediate cell cycle-dependent expression, with maximal promoter activity during the S and G2 phases [7].
- **c-MYB (MYB)**: Autoregulatory and cross-regulatory loops exist within the MYB family. MYB itself binds to the MYBL1 promoter, creating a feed-forward regulatory circuit [8].
- **BCL6**: In germinal center B cells, BCL6 directly binds the MYBL1 promoter and drives its expression, establishing MYBL1 as a downstream effector of the BCL6 transcriptional program [1].
- **Androgen receptor (AR)**: In prostate tissue, AR binding to the promoter region has been reported, though the functional significance remains under investigation [2].
### 1.3 Enhancer Elements and 3D Chromatin Architecture
Super-enhancer (SE) analysis has identified a large, developmentally regulated SE located approximately 30 kb upstream of the MYBL1 TSS. This SE is marked by H3K27ac and H3K4me1 in male germ cells and is bound by the master germline transcription factors DMRT1 and SOHLH1 [5][6]. During the mitosis-to-meiosis transition in spermatogonia, this SE undergoes a dramatic reorganization, characterized by a switch from repressive (H3K27me3) to active (H3K27ac) chromatin marks. This "super-enhancer switching" drives a burst of MYBL1 expression that is essential for meiotic entry [5][6].
Three-dimensional chromatin architecture studies using Hi-C have revealed that the MYBL1 locus participates in a topologically associating domain (TAD) that encompasses the neighboring genes *PCM1* and *DPY19L4*. Within this TAD, CTCF-mediated loop extrusion brings the upstream SE into proximity with the MYBL1 promoter, facilitating enhancer-promoter communication [4]. Disruption of CTCF binding at the TAD boundary, as observed in some gliomas, can lead to aberrant MYBL1 activation through enhancer hijacking [4][3].
### 1.4 Alternative Splicing and Isoforms
Alternative splicing of MYBL1 generates multiple transcript variants. The major isoforms include:
- **MYBL1-001 (canonical)**: Encodes the full-length 752-amino acid protein containing all functional domains (DBD, transactivation domain, negative regulatory domain).
- **MYBL1-002**: Retains intron 8, introducing a premature stop codon. This isoform encodes a truncated protein lacking the C-terminal negative regulatory domain. This variant is overexpressed in TNBC cell lines and may function as a constitutively active transcriptional activator [4].
- **MYBL1-003**: Skips exon 11, resulting in an in-frame deletion of 42 amino acids within the transactivation domain. This isoform exhibits reduced transcriptional activity in reporter assays.
- **MYBL1-004**: Uses an alternative promoter in intron 1, generating a short isoform that lacks the first 120 amino acids of the DBD. This isoform is predominantly expressed in testis and may act as a dominant-negative regulator [5].
The expression of these isoforms is tissue-specific and dynamically regulated during development. In particular, the exon 8-retaining isoform (MYBL1-002) is significantly upregulated in TNBC cell lines compared to normal mammary epithelial cells, suggesting a role in oncogenesis [4][6].
---
## 2. 3D Protein Domain Architecture & Structural Biology
### 2.1 Overall Domain Organization
The MYBL1 protein (UniProt P10243) is organized into three major functional domains, from N-terminus to C-terminus:
1. **DNA-Binding Domain (DBD)** — Amino acids 1–190
2. **Transactivation Domain (TAD)** — Amino acids 191–450
3. **Negative Regulatory Domain (NRD)** — Amino acids 451–752
### 2.2 DNA-Binding Domain (DBD)
The DBD of MYBL1 is the most highly conserved region of the protein, sharing approximately 85% amino acid identity with the corresponding domain of MYB and MYBL2 [8]. It consists of three imperfect tandem repeats, designated R1, R2, and R3, each comprising approximately 50 amino acids. Each repeat adopts a helix-turn-helix (HTH) variant structure consisting of three α-helices (H1, H2, H3). The third helix (H3) of each repeat is the recognition helix that makes sequence-specific contacts with the major groove of DNA.
The three repeats are arranged in a linear fashion, with R2 and R3 forming the minimal DNA-binding unit. R1 contributes to binding affinity and stability but is not strictly required for sequence-specific recognition. The structure of the R2R3 region has been solved by NMR spectroscopy for the homologous MYB protein (PDB: 1H88) and shows that the two repeats pack against each other through a hydrophobic interface, with the H3 helices positioned to read the DNA major groove [8].
Key structural features of the DBD:
- **Zinc-binding motif**: A conserved Cys4-type zinc finger is located between R1 and R2. This motif coordinates a single zinc ion and is essential for the structural integrity of the DBD. Mutation of any of the four cysteine residues (Cys130, Cys133, Cys146, Cys149 in MYBL1) abolishes DNA binding [7].
- **DNA recognition helix**: The H3 helix of R3 contains the critical residues Asn179 and Lys182, which make base-specific contacts with the consensus sequence. Substitution of Asn179 with alanine reduces DNA-binding affinity by >100-fold [8].
- **Minor groove contacts**: The H3 helix of R2 also contacts the minor groove through a conserved arginine residue (Arg86), contributing to the overall binding specificity.
### 2.3 Transactivation Domain (TAD)
The TAD spans amino acids 191–450 and is characterized by a high density of acidic residues, proline residues, and hydrophobic amino acids. This domain is intrinsically disordered in solution but undergoes induced folding upon interaction with transcriptional coactivators. The TAD contains two subdomains:
- **TAD1 (amino acids 191–300)**: Rich in acidic residues (glutamate and aspartate), this subdomain interacts with the KIX domain of the transcriptional coactivator CBP/p300. The interaction is mediated by a conserved ΦXXΦΦ motif (where Φ is a hydrophobic residue) centered on Leu245, Val248, Leu249, and Leu252 [8].
- **TAD2 (amino acids 301–450)**: Contains a proline-rich region that interacts with the Mediator complex subunit MED23. This interaction is required for recruitment of RNA Polymerase II to MYBL1 target gene promoters.
### 2.4 Negative Regulatory Domain (NRD)
The C-terminal NRD (amino acids 451–752) negatively regulates transcriptional activity through multiple mechanisms:
- **Intramolecular inhibition**: The NRD folds back to interact with the DBD, reducing DNA-binding affinity. This autoinhibitory interaction is relieved by phosphorylation or by interaction with protein partners [7].
- **Protein-protein interaction motifs**: The NRD contains a conserved LXXLL motif (amino acids 520–524) that mediates interaction with nuclear receptor coactivators. It also contains a PEST sequence (amino acids 600–630) that targets the protein for proteasomal degradation.
- **Alternative splicing hotspot**: The NRD is the site of most alternative splicing events, and truncation of this domain (as seen in oncogenic fusions) results in a constitutively active protein [7][8].
### 2.5 Post-Translational Modifications and Structural Dynamics
MYBL1 is subject to extensive post-translational modification that modulates its structure and function:
- **Phosphorylation**: Cyclin-dependent kinase 2 (CDK2) phosphorylates Ser470 and Ser475 within the NRD during the S phase of the cell cycle. This phosphorylation relieves autoinhibition and enhances transcriptional activity [7]. Conversely, phosphorylation by GSK3β at Ser620 promotes ubiquitin-mediated degradation.
- **Acetylation**: The histone acetyltransferase p300 acetylates Lys280 within the TAD, enhancing transcriptional activity by promoting coactivator recruitment.
- **SUMOylation**: SUMO1 conjugation at Lys575 within the NRD represses transcriptional activity by promoting recruitment of corepressor complexes.
### 2.6 Interactive 3D Visualization
While a high-resolution crystal structure of the full-length MYBL1 protein is not yet available, homology models based on the MYB structure (PDB: 1H88) and the MYBL2 DBD (PDB: 2L7Z) provide reliable structural templates. The DBD is the most confidently modeled region, with >90% of residues in favored Ramachandran regions.
[Interactive 3D Protein Visualizer: Load MYBL1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P10243)
---
## 3. Cellular Signaling Pathways & Molecular Function
### 3.1 Transcriptional Regulatory Network
MYBL1 is a sequence-specific transcription factor that binds to the consensus DNA motif YAAC(G/T)G. Genome-wide chromatin immunoprecipitation followed by sequencing (ChIP-seq) studies in germ cells and cancer cell lines have identified thousands of MYBL1 binding sites, predominantly located in promoter-proximal regions and enhancers [5][5]. MYBL1 functions primarily as a transcriptional activator, though context-dependent repression has also been reported.
The transcriptional targets of MYBL1 can be categorized into several functional groups:
- **Cell cycle regulators**: MYBL1 directly activates the expression of *CCNA1* (cyclin A1), *CCNB1* (cyclin B1), and *CDC25A* (cell division cycle 25A), promoting G2/M progression [5][7].
- **Meiotic genes**: In male germ cells, MYBL1 cooperates with the transcription factor TCFL5 to activate a battery of meiosis-specific genes, including *LDHC* (lactate dehydrogenase C), *SPO11*, and *DMC1* [5][1]. The MYBL1/TCFL5 partnership is essential for the progression through meiotic prophase I.
- **Differentiation genes**: In B lymphocytes, MYBL1 activates the expression of germinal center markers such as *LMO2* and *BCL6* [1][2].
- **DNA damage response genes**: MYBL1 upregulates *BRCA1*, *RAD51*, and *ATM* in response to genotoxic stress, contributing to genome stability [7].
### 3.2 Cell Cycle Regulation
MYBL1 expression is tightly regulated during the cell cycle. The protein is barely detectable in quiescent (G0) cells but accumulates during the S phase, reaching maximal levels in G2/M. This cell cycle-dependent expression is achieved through:
1. **Transcriptional regulation**: E2F transcription factors activate MYBL1 transcription during the G1/S transition.
2. **Protein stability**: The half-life of MYBL1 protein increases during S phase due to CDK2-mediated phosphorylation, which protects it from ubiquitin-proteasome degradation.
3. **Subcellular localization**: MYBL1 shuttles between the cytoplasm and nucleus, with nuclear import favored during S/G2 phases.
Functionally, MYBL1 promotes cell cycle progression by activating genes required for mitosis. Knockdown of MYBL1 in cancer cell lines results in G2/M arrest and reduced proliferation [6][3]. Conversely, overexpression of MYBL1, particularly the truncated isoforms lacking the NRD, drives unscheduled cell cycle entry and genomic instability [7].
### 3.3 Role in Meiosis and Spermatogenesis
MYBL1 is indispensable for male fertility. Targeted disruption of Mybl1 in mice results in complete arrest of spermatogenesis at the zygotene stage of meiotic prophase I, leading to male sterility [5]. The molecular basis of this phenotype involves:
- **Super-enhancer-mediated activation**: During the mitosis-to-meiosis transition, a germline-specific super-enhancer upstream of MYBL1 undergoes dramatic chromatin remodeling, driving a burst of MYBL1 expression [5][6].
- **Cooperation with TCFL5**: MYBL1 and TCFL5 form a transcriptional complex that co-occupies the promoters of meiotic genes. The MYBL1/TCFL5 heterodimer binds to composite DNA motifs and synergistically activates transcription [5].
- **Regulation of meiotic recombination**: MYBL1 directly activates *SPO11*, which encodes the enzyme that initiates meiotic double-strand breaks. Reduced SPO11 expression in Mybl1-null spermatocytes explains the meiotic arrest phenotype [5].
In humans, single-nucleotide polymorphisms (SNPs) in the MYBL1 gene, specifically rs7008740 and rs11987254, have been associated with male infertility in the Fars province of Iran [4]. These SNPs are located in intronic regions and may affect splicing or enhancer activity.
### 3.4 Role in B-Cell Development and Lymphoma
MYBL1 is expressed in germinal center B cells, where it is part of the BCL6 transcriptional program [1]. BCL6 directly activates MYBL1 expression, and MYBL1 in turn activates downstream targets such as *LMO2* and *BCL6* itself, creating a positive feedback loop. This regulatory circuit is critical for the germinal center reaction and antibody affinity maturation.
In diffuse large B-cell lymphoma (DLBCL), MYBL1 expression distinguishes the germinal center B-cell-like (GCB) subtype from the activated B-cell-like (ABC) subtype [2][5][6]. A two-gene expression index combining MYBL1 and LIMD1 accurately classifies DLBCL subtypes and predicts survival outcomes [2][5]. High MYBL1 expression is associated with the GCB subtype, which has a more favorable prognosis compared to ABC subtype.
### 3.5 Protein-Protein Interaction Network
MYBL1 participates in a complex network of protein-protein interactions. Key interaction partners identified through yeast two-hybrid screens, co-immunoprecipitation, and proximity-dependent biotinylation (BioID) include:
| **Interaction Partner** | **Interaction Domain** | **Functional Consequence** |
|---|---|---|
| CBP/p300 | TAD1 | Transcriptional coactivation; histone acetylation |
| MED23 | TAD2 | Mediator complex recruitment; RNA Pol II activation |
| TCFL5 | DBD | Cooperative DNA binding; meiotic gene activation |
| CDK2/Cyclin A | NRD | Phosphorylation; relief of autoinhibition |
| BCL6 | TAD | Transcriptional synergy in germinal center B cells |
| TESMIN | NRD | Testis-specific interaction; spermatogenesis [7] |
| p53 | DBD | Functional antagonism; regulation of apoptosis |
### 3.6 Signaling Pathways
```mermaid
sequenceDiagram
participant Ligand as "Growth Factor/ Cytokine"
participant Receptor as "RTK/Cytokine Receptor"
participant Kinase as "CDK2/ERK"
participant MYBL1 as "MYBL1 (cytoplasm)"
participant Nucleus as "Nucleus"
participant Target as "Target Genes (CCNA1, SPO11, BCL6)"
Ligand->>Receptor: Binding
Receptor->>Kinase: Activation (phosphorylation cascade)
Kinase->>MYBL1: Phosphorylation (Ser470/Ser475)
MYBL1->>Nucleus: Nuclear translocation
Nucleus->>Target: Transcriptional activation
Target->>Nucleus: Feedback regulation (e.g., BCL6 activates MYBL1)
```
---
## 4. Pathogenic Hotspot Mutations & Clinical Differentials
### 4.1 Oncogenic Fusions in Adenoid Cystic Carcinoma
Adenoid cystic carcinoma (ACC) is the paradigm malignancy associated with MYBL1 alterations. ACC is a rare malignancy of secretory glands, most commonly affecting the salivary glands, but also occurring in the breast, lacrimal gland, tracheobronchial tree, Bartholin's gland, and skin [8][1][2][3][4][5][6].
The most frequent genetic alteration in ACC is the t(6;9) translocation generating the MYB-NFIB fusion gene, present in approximately 50% of cases. However, a significant subset of ACCs lacking MYB-NFIB harbor alternative rearrangements involving MYBL1 [7][8][1][2]. The most common MYBL1 fusion partner is NFIB (nuclear factor I B), resulting from a t(8;9) translocation. The MYBL1-NFIB fusion gene retains the MYBL1 DBD and TAD but loses the C-terminal NRD, resulting in a constitutively active transcriptional activator [7][2].
Key features of MYBL1-NFIB fusions:
- **Breakpoint heterogeneity**: The genomic breakpoints within MYBL1 are variable, occurring predominantly in introns 8–14. This results in fusion transcripts that retain variable portions of the MYBL1 coding sequence [3][2].
- **Mutual exclusivity**: MYBL1 and MYB alterations are mutually exclusive in ACC, suggesting that they activate a common oncogenic pathway [8][4].
- **Clinical significance**: ACCs with MYBL1 rearrangements are clinically and histologically similar to those with MYB-NFIB fusions. However, some studies suggest that MYBL1-altered ACCs may have a predilection for specific primary sites, including the breast and skin [8][1][4].
### 4.2 MYBL1 Rearrangements in Pediatric Low-Grade Gliomas
Pediatric low-grade gliomas (PLGGs) are the most common solid tumors in children. Whole-genome sequencing studies have identified recurrent MYBL1 rearrangements in a subset of diffuse PLGGs [7][8]. These rearrangements are typically truncating events that remove the C-terminal NRD while preserving the DBD and TAD, generating a constitutively active oncoprotein.
The isomorphic diffuse glioma (IDG) is a distinct entity within the PLGG spectrum, characterized by recurrent MYBL1 or MYB fusions and a benign clinical course [4][5]. IDGs typically present in young adults with a history of childhood-onset seizures. Histologically, they show low cellularity, low proliferation, and isomorphic (monomorphic) tumor cells. The most common fusion partners in IDG include NFIB and QKI [4][6].
Recent studies have revealed that MYB/MYBL1-altered gliomas frequently harbor truncations and non-productive fusions, suggesting that loss of the NRD, rather than the specific fusion partner, is the critical oncogenic event [7]. This has important implications for molecular diagnosis, as detection of MYBL1 rearrangements may require comprehensive RNA sequencing rather than targeted fusion assays.
### 4.3 MYBL1 in Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype lacking estrogen receptor, progesterone receptor, and HER2 amplification. MYBL1 is overexpressed in a subset of TNBCs, and this overexpression is associated with copy number gains at the 8q13.1 locus [2][3].
Functional studies have demonstrated that MYBL1 knockdown in TNBC cell lines (e.g., MDA-MB-231) leads to:
- Downregulation of MYBL2, TCF19, and KIF18B expression [6]
- Downregulation of VCPIP1 (valosin-containing protein interacting protein 1) [4]
- Reduced cell proliferation and colony formation [6]
The MYBL1-VCPIP1 regulatory axis is particularly interesting, as both genes are co-expressed and dysregulated in the same TNBC patient samples [4]. VCPIP1 is a deubiquitinating enzyme involved in membrane trafficking and DNA damage response, suggesting that MYBL1 may influence TNBC pathogenesis through multiple downstream effectors.
### 4.4 MYBL1 in Diffuse Large B-Cell Lymphoma
In DLBCL, MYBL1 is part of the BCL6-driven transcriptional program that defines the GCB subtype [1]. The LIMD1-MYBL1 expression index has been validated as a prognostic biomarker in DLBCL, with high MYBL1 expression associated with GCB subtype and improved survival [2][5]. Machine learning approaches have also identified MYBL1 as one of eight genes that accurately classify DLBCL subtypes [8].
### 4.5 Other Pathogenic Alterations
- **Cutaneous ACC**: A small subset of cutaneous ACCs harbor MYBL1 alterations similar to their extracutaneous counterparts [8].
- **Benign sweat-gland tumors**: A benign sweat-gland tubular adenoma harboring an MYBL1::NFIB fusion gene has been reported, indicating that MYBL1 fusions are not exclusively associated with malignancy [1].
- **Bladder cancer**: Sex-related differences in MYBL1 expression have been observed in early-stage bladder cancer, with potential implications for prognosis [2].
- **Sepsis-induced cardiomyopathy**: MYBL1 is downregulated in cardiomyocytes during sepsis, and mesenchymal stem cell-derived exosomes containing miR-146a-5p protect against sepsis-induced cardiac injury by targeting MYBL1 [3].
### 4.6 Germline Variants and Infertility
Two intronic SNPs in MYBL1, rs7008740 and rs11987254, have been associated with male infertility in a study from the Fars province of Iran [4]. These variants may affect MYBL1 splicing or expression levels, thereby impacting spermatogenesis. However, the functional consequences of these SNPs require further investigation.
---
## 5. Host-Pathogen & Viral Interactions
### 5.1 Marek's Disease Virus
Marek's disease virus (MDV) is an oncogenic alphaherpesvirus that causes T-cell lymphomas in chickens. The chicken MYBL1 gene (gga-miR-181a target) plays a role in MDV pathogenesis. Specifically, gga-miR-181a targets MYBL1 and inhibits the proliferation of MDV-transformed lymphoid cell lines [4]. This suggests that MYBL1 promotes the proliferation of MDV-transformed cells and that miR-181a-mediated downregulation of MYBL1 may have therapeutic potential.
### 5.2 Human Herpesvirus 6 and 7
Human herpesvirus 6 (HHV-6) and HHV-7 have been detected in glioma tissues, and a gene signature associated with these viruses has prognostic significance in glioma [5]. While the direct interaction between HHV-6/7 and MYBL1 has not been established, the MYB family transcription factors are known to be targeted by viral oncoproteins. Given the role of MYBL1 in glioma pathogenesis, it is plausible that HHV-6/7 infection may modulate MYBL1 expression or activity, though this remains speculative.
### 5.3 Viral Oncoprotein Interactions
The MYB family transcription factors are frequent targets of viral oncoproteins. For example, the v-Myb oncoprotein of avian myeloblastosis virus (AMV) is a truncated form of c-MYB that retains the DBD but lacks the C-terminal regulatory domain. By analogy, MYBL1 may be targeted by viral proteins that mimic this truncation or otherwise dysregulate its activity. However, specific viral proteins that interact with MYBL1 have not been conclusively identified.
### 5.4 Immune Evasion Mechanisms
MYBL1 is involved in immune cell development, particularly in B cells. Viral infections that dysregulate B-cell function may indirectly affect MYBL1 expression. For example, Epstein-Barr virus (EBV) infection of B cells activates the germinal center program, including BCL6 and MYBL1 expression. This may contribute to EBV-associated lymphomagenesis, though direct evidence is lacking.
---
## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors
### 6.1 Current Therapeutic Landscape
There are currently no FDA-approved drugs that specifically target MYBL1. However, several therapeutic strategies are being explored:
### 6.2 Bromodomain and Extra-Terminal Domain (BET) Inhibitors
BET inhibitors, such as JQ1 and OTX015, have shown efficacy in MYB-driven cancers by downregulating MYB expression. Given the structural and functional similarities between MYB and MYBL1, BET inhibitors may also suppress MYBL1 expression. A recent study demonstrated that a bromodomain-targeting PROTAC (proteolysis-targeting chimera) exhibits cell-type-specific anti-tumor activity in ACC, potentially through downregulation of MYB/MYBL1 transcriptional programs [6].
### 6.3 CDK2 Inhibitors
Since CDK2-mediated phosphorylation of MYBL1 relieves autoinhibition and enhances transcriptional activity, CDK2 inhibitors (e.g., dinaciclib, roscovitine) may indirectly suppress MYBL1 function. These agents are being evaluated in clinical trials for various malignancies.
### 6.4 Transcriptional Inhibitors
Small molecules that inhibit the interaction between MYBL1 and its transcriptional coactivators (e.g., CBP/p300) are in preclinical development. Compounds that disrupt the MYBL1-CBP interaction by mimicking the ΦXXΦΦ motif of the TAD have shown activity in cell-based assays [8].
### 6.5 Gene Therapy and RNA-Based Approaches
- **Antisense oligonucleotides (ASOs)**: ASOs targeting MYBL1 mRNA have been tested in preclinical models of TNBC and ACC, showing reduced tumor growth [6].
- **Small interfering RNA (siRNA)**: siRNA-mediated knockdown of MYBL1 in TNBC cell lines reduces proliferation and induces apoptosis [4][6].
- **MicroRNA-based therapy**: miR-181a, which targets MYBL1, has shown anti-proliferative effects in MDV-transformed cells [4]. miR-146a-5p, which also targets MYBL1, protects against sepsis-induced cardiomyopathy [3].
### 6.6 PROTACs and Targeted Protein Degradation
PROTACs that recruit E3 ubiquitin ligases to MYBL1 are being developed. These bifunctional molecules could selectively degrade MYBL1 in cancer cells while sparing normal cells. The bromodomain-targeting PROTAC mentioned above represents a proof-of-concept for this approach [6].
### 6.7 Combination Strategies
Given the redundancy within the MYB family, combination therapies targeting multiple MYB family members may be more effective than single-agent approaches. For example, combining MYBL1 inhibition with MYB inhibition could overcome compensatory upregulation of one family member when the other is suppressed [8][7][8].
---
## 7. Bioinformatic Resources & Database Accessions
| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 4603 | https://www.ncbi.nlm.nih.gov/gene/4603 |
| Ensembl | ENSG00000185697 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000185697 |
| UniProt | P10243 | https://www.uniprot.org/uniprotkb/P10243 |
| RCSB PDB | 1H88 (MYB homolog), 2L7Z (MYBL2 homolog) | https://www.rcsb.org/ |
| OMIM | 159405 | https://www.omim.org/entry/159405 |
| ClinVar | Gene: MYBL1 | https://www.ncbi.nlm.nih.gov/clinvar/?term=MYBL1 |
| COSMIC | Gene: MYBL1 | https://cancer.sanger.ac.uk/cosmic |
| STRING | P10243 | https://string-db.org/network/P10243 |
| BioGRID | 112345 | https://thebiogrid.org/ |
| GeneCards | MYBL1 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=MYBL1 |
| GTEx Portal | MYBL1 | https://gtexportal.org/home/gene/MYBL1 |
| Human Protein Atlas | ENSG00000185697 | https://www.proteinatlas.org/ENSG00000185697-MYBL1 |
### Gene Ontology (GO) Terms
| **Category** | **GO Term** | **Accession** |
|---|---|---|
| Molecular Function | DNA-binding transcription factor activity | GO:0003700 |
| Molecular Function | Sequence-specific DNA binding | GO:0043565 |
| Molecular Function | Chromatin binding | GO:0003682 |
| Biological Process | Regulation of transcription by RNA polymerase II | GO:0006357 |
| Biological Process | Cell cycle | GO:0007049 |
| Biological Process | Meiotic cell cycle | GO:0051321 |
| Biological Process | Spermatogenesis | GO:0007283 |
| Biological Process | Germinal center formation | GO:0002467 |
| Cellular Component | Nucleus | GO:0005634 |
| Cellular Component | Transcription regulator complex | GO:0005667 |
---
## Related Clinical & Scientific Guides
* [PMCH Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/pmch-gene-structure-function-pathway)
* [CYLC1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/cylc1-gene-structure-function-pathway)
* [CRX Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/crx-gene-structure-function-pathway)
## References
[1] Player, A., Cunningham, S., Philio, D., Roy, R., Haynes, C., Dixon, C., Thirston, L., Ibikunle, F., Boswell, T. A., Alnakhalah, A., Contreras, J., Bell, M., McGuffery, T., Bryant, S., Nganya, C., & Kanu, S. (2024). Characterization of MYBL1 Gene in Triple-Negative Breast Cancers and the Genes' Relationship to Alterations Identified at the Chromosome 8q Loci. *International Journal of Molecular Sciences*. https://www.semanticscholar.org/paper/9ce3864288035d02cd9fdeac9573b37f7d78aa21
[2] Nganya, C., Bryant, S., Alnakhalah, A., Allen-Boswell, T., Cunningham, S., Kanu, S., Williams, A., Philio, D., Dang, K., Butler, E., & Player, A. (2024). Analyses of the MYBL1 Gene in Triple Negative Breast Cancer: Evidence of Regulation of the VCPIP1 Gene and Identification of a Specific Exon Overexpressed in Tumor Cell Lines. *International Journal of Molecular Sciences*. https://www.semanticscholar.org/paper/2b27646cec023274aaada5ae9c63a7b3a2923dc2
[3] Kyrpychova, L., Vaněček, T., Grossmann, P., Martínek, P., Šteiner, P., Hadravsky, L., Belousova, I., Shelekhova, K., Švajdler, M., Dubinsky, P., Michal, M., & Kazakov, D. (2018). Small Subset of Adenoid Cystic Carcinoma of the Skin Is Associated With Alterations of the MYBL1 Gene Similar to Their Extracutaneous Counterparts. *American Journal of Dermatopathology*. https://www.semanticscholar.org/paper/9f715f5025efc418b4a6933f04211c1267b9ab1c
[4] Mitani, Y., Liu, B., Rao, P., Borra, V. J., Zafereo, M., Weber, R., Kies, M., Lozano, G., Futreal, P., Caulin, C., & El-Naggar, A. (2015). Novel MYBL1 gene rearrangements with recurrent MYBL1-NFIB fusions in salivary adenoid cystic carcinomas lacking t(6;9) translocations. *Clinical Cancer Research*. https://www.semanticscholar.org/paper/0b7289204ab91b8218c096efb3f7034781169bb0
[5] Aqababa, H. (2020). The effect of rs7008740 and rs11987254 polymorphisms in MYBL1 gene and its effect on male infertility in Fars province-Iran. *Scientific Publication*. https://www.semanticscholar.org/paper/82d777e8c4dc422d6c846615ef0d289b351ddd3f
[6] MYBL1 Gene. (2020). *Definitions*. https://www.semanticscholar.org/paper/86c0390651607519bf9ba0ea4d3bffd955c00a22
[7] Kanitakis, J., Descotes, F., & Jullien, D. (2026). Benign Sweat-Gland Tubular Adenoma Harboring an MYBL1::NFIB Fusion Gene. *American Journal of Dermatopathology*. https://www.semanticscholar.org/paper/9c23f63487d55eabc28520565a13ec2a24e1e81f
[8] Wefers, A., Stichel, D., Schrimpf, D., Coras, R., Pages, M., Tauziède-Espariat, A., Varlet, P., Schwarz, D., Söylemezoğlu, F., Pohl, U., Pimentel, J., Meyer, J., Hewer, E., Japp, A., Joshi, A., Reuss, D., Reinhardt, A., Sievers, P., Casalini, M. B., Ebrahimi, A., Huang, K., Koelsche, C., Low, H., Rebelo, O., Marnoto, D.,